84 results about "Anticancer drug" patented technology

Disclosed are a CD24 antibody or an antigen-binding fragment thereof and the medical use thereof. Further, disclosed are a chimeric antibody comprising CDRs of the CD24 antibody, a humanized antibody, a pharmaceutical composition comprising the CD24 antibody or the antigen-binding fragment thereof, and the use thereof as an anticancer drug.

The application relates to the technical field of natural medicinal chemistry, and specifically discloses a triterpenoid compound and application, and a preparation method of the compound. The preparation method comprises the following steps: drying and crushing schisandra chinensis roots to obtain dried and crushed schisandra chinensis roots, extracting the dried and crushed schisandra chinensis roots by using 70% ethanol water solution under negative pressure cavitation, combining and concentrating the extract to obtain a crude extract, separating the crude extract by using a D101 macroporous adsorption resin, eluting the crude extract by using water, 30% ethanol, 70% ethanol and 90% ethanol in sequence, collecting a 70% ethanol elution part, performing MCI column chromatography on the 70% ethanol elution part, performing gradient elution on the 70% ethanol elution part by using methanol-water, collecting a depigmentation sample, performing ODS column chromatography on the depigmentation sample, performing gradient elution on the depigmentation sample by using water-methanol, collecting a target component, and purifying the target component by using a preparative high performance liquid chromatograph to obtain the target compound. The application separates a novel triterpenoid compound from schisandra chinensis roots for the first time, expands the development range of medicinal resources of schisandra chinensis plants, simultaneously provides a novel structure mother nucleus and a candidate active molecule for anticancer drug research and development, and enriches the research and development reserves of antitumor natural medicines.

This invention proposes a mechanism-aware synergistic anticancer drug combination prediction method and system, belonging to the field of biomedical technology. It includes: extracting node-level feature representations of the first and second drugs through a drug encoder, and extracting molecular representations of the cell line through a cell line encoder; generating an attention tensor based on a trilinear cross-modal synergistic strategy using a trilinear attention network to explicitly capture the synergistic dependencies of the drug combination in a specific cellular environment, and updating and enhancing the features through context fusion; finally, concatenating the enhanced features and outputting a synergistic score via a multilayer perceptron. This invention can directly model the joint interaction relationship between the first drug, the second drug, and the cell line, thereby accurately predicting the synergistic effect of the anticancer drug combination.

This disclosure describes how to treat and / or improve pancreatic cancer using a novel proteomic profile of the pancreatic cancer. In some embodiments, the treatment includes removing cancerous tissue after taking a biopsy from the patient. Optionally, the treatment includes administering anticancer agents to suppress the progression of pancreatic cancer. In further or alternative embodiments, the novel proteomic profile is used to monitor disease progression or remission.

This invention discloses a polysubstituted indole[1,2-a]quinoxaline compound, its preparation method, and its applications. The structural formula of the polysubstituted indole[1,2-a]quinoxaline compound of this invention is or , where R 1 Selected from -H or -F, R 2 The compounds are selected from phenyl, 4-methylphenyl, 4-methoxyphenyl, or 4-fluorophenyl. The polysubstituted indole[1,2-a]quinoxaline compounds of this invention have novel structures and significant antitumor activity, making them suitable for the synthesis of anticancer drugs. Furthermore, their preparation methods offer advantages such as readily available and inexpensive catalysts, broad substrate applicability, good functional group tolerance, simple operation, mild reaction conditions, and high step economy, making them suitable for large-scale industrial production and application.

This application belongs to the field of anticancer drug technology, specifically relating to a prostate cancer-targeted verteporfen, its preparation method, and its application. The prostate cancer-targeted verteporfen has the chemical formula shown as Formula I in the specification. The prostate cancer-targeted verteporfen provided in this application has good water solubility and targeting properties, enabling effective delivery to the target site. Combined with ultrasound physical stimulation, it can achieve in-situ generation of reactive oxygen species in the tumor, releasing verteporfen and reactive oxygen species, effectively enhancing the killing effect on tumor cells.

A traditional Chinese medicine composition for inhibiting or reducing breast cancer cells comprises Euphorbia kansui, Paeonia lactiflora, Glycyrrhiza uralensis, Taraxacum mongolicum, Gardenia jasminoides, and Hordeum vulgare. The weight ratio of Euphorbia kansui, Paeonia lactiflora, Glycyrrhiza uralensis, Taraxacum mongolicum, Gardenia jasminoides, and Hordeum vulgare in the traditional Chinese medicine composition is 1-2:4-6:2-3:3-5:2-4:2-3. This traditional Chinese medicine composition is intended for the preparation of anticancer drugs. The composition is administered to breast cancer cells at an effective dose between 0.1 and 10 mg / ml for culturing. Cell experiments have confirmed that the traditional Chinese medicine composition exhibits inhibitory activity against breast cancer cells, thereby achieving the purpose of treating breast cancer symptoms or inhibiting breast cancer cell activity.

The present invention relates to an animal model for research on cancer immunotherapy agents, and a preparation method therefor. A nude mouse, which is a mouse model widely used for evaluating the effects of anticancer agents, can verify the efficacy of a cytotoxic anticancer agent, but cannot confirm the effect of an cancer immunotherapy agent because immune function is deficient. However, a cancer animal model according to the present invention has normal immune function, thereby enabling preclinical efficacy of a cancer immunotherapy agent to be accurately predicted, and thus is expected to contribute to improving the prognosis of a patient for whom surgery is not possible.

This invention provides a method for preparing 2-alkylthiobenzo[b]thiophene sulfone compounds. Using acylsulfonylmethylthio ylide compounds as raw materials, cyclization in the presence of an acid anhydride or acyl halide is induced to achieve the preparation of 2-alkylthiobenzo[b]thiophene sulfone compounds. This preparation method uses readily available and simple raw materials and is easy to operate. The obtained compounds can be applied to important organic materials, such as luminescent materials, antibacterial and anticancer drugs, and pesticides. They can also be used as intermediates in the synthesis of organic materials and drugs, and for the preparation of various materials and drugs.

This invention discloses a method for assessing the sensitivity of anticancer drugs based on patient-derived tumor tissue, belonging to the field of biomedical technology. The method includes: obtaining fresh tumor tissue from a patient and preparing it into tissue fragments of approximately 1 mm³; culturing the tissue fragments in vitro in a three-dimensional gel matrix; adding the anticancer drug to be tested to the culture system; digesting the tissue fragments after culture to obtain a single-cell suspension; and assessing drug sensitivity by detecting cell viability using flow cytometry. This invention can maximally preserve tumor heterogeneity and microenvironment, has a short operation cycle, and can quickly and accurately guide personalized clinical medication, especially suitable for solid tumors such as brain tumors.

The invention relates to a method to indicate the clinical outcome of a cancer patient by labelling a cancer sample with labelled molecular probes, assaying the expression of a plurality of biomolecules at the resolution of a single cell and assigning a cellular identity (CI) to each single cell in the sample based on their expression pattern; then assigning a single cell pathology (SCP) patient group according to the proportion of each CI the sample contains.The invention in other aspects relates to methods of treatment of a patient with anticancer drugs according to the patient's assignment to particular SCPs. Alternatively, this aspect may be formulated as the provision of certain drugs for treatment of cancer in patients characterized by tumours assigned to certain SCPs.

Disclosed herein is a method for predicting whether a subject with cancer will exhibit a beneficial response to arginine deficiency therapy. The method includes the step of determining the plasma concentration of arginine in the subject, followed by administering arginine deficiency therapy to the subject alone or in combination with an anticancer agent, based on the determined plasma concentration of arginine. According to some embodiments of this disclosure, the anticancer agent is selected from the group consisting of FOLFOX, docetaxel, cisplatin, pemetrexed, pembrolizumab, and combinations thereof.

The application provides a method for synchronously detecting multiple cell death modes in a tissue slice based on multiplex immunofluorescence, and belongs to the technical field of biological detection. The application realizes the synchronous labeling and visualization of multiple cell death modes in a single tissue slice, significantly improves the detection efficiency and saves precious samples; by integrating key biomarkers covering main cell death modes in the same detection system, a self-defined interpretation scheme based on multi-marker expression combination is constructed, effectively reducing the error caused by non-specific expression of a single marker, improving the reliability and rationality of the death mode classification, and providing a general solution for rapid screening of complex cell death networks. The application is suitable for anticancer drug efficacy evaluation, combination drug regimen screening and disease mechanism research, and has important scientific research value and clinical conversion prospect.

The application provides a colorimetric-fluorescent dual-mode determination method for hydrophobic anticancer drug curcumin, and the application realizes the preparation of oil amine branch joint polysuccinimide loaded curcumin (CUR@PSI OAm ) coated antigen, dual-mode probe labeled anti-PSI OAm antibody, and specific combination of antigen-antibody reaction for dual-mode ultra-trace detection and analysis of CUR@PSI OAm in cells, and indirect quantitative detection of hydrophobic anticancer drug curcumin in cells. Compared with the prior art, the dual-mode analysis method provided by the application can be mutually supported, and does not need to be enriched and preprocessed, is simple to operate, has short detection time, has the characteristics of high throughput, high sensitivity, high specificity, precise targeting and non-destructive detection, and can be used for ultra-trace non-destructive detection and analysis of hydrophobic anticancer drug curcumin (CUR) in cells.

The application provides a novel anticancer drug TNBG-sugar conjugate and a preparation and application thereof, and belongs to the field of chemical medicines.The conjugate is a compound shown in formula I and formula IV or a salt or a stereoisomer thereof.The anticancer drug TNBG-sugar conjugate and a preparation prepared by using suitable excipients or auxiliary ingredients have a good inhibitory effect on cancer cells such as lung cancer and liver cancer, have low or basically no toxicity to normal cells, can be used for the prevention and treatment of lung cancer, liver cancer and other cancers, and have a good application prospect.

This invention relates to a macromolecular anticancer drug and a method for preparing it with controllable molecular weight. The macromolecular copper chelating agent of this invention possesses excellent copper ion binding capacity, significant copper-reducing effect, good safety profile, and good therapeutic and preventative effects against cancer. The method for preparing the controllable molecular weight of this invention is simple, has high yield, uses inexpensive and readily available raw materials, and operates under mild reaction conditions. It enables the large-scale, simple, and efficient preparation of the polymer of this invention, and allows for precise control of its molecular weight, thereby obtaining a macromolecular anticancer drug with a long metabolic time in vivo and good therapeutic effect on cancer metastasis.

This invention discloses an alkaloid, its preparation method, and its application in the preparation of human carboxylesterase 2 inhibitors. The residue of Paeonia lactiflora after ultrasonic extraction was extracted with 95% ethanol and then with ethyl acetate to obtain ethyl acetate extract CS-5. Separation was performed by silica gel column chromatography, using a gradient elution with petroleum ether-acetone mixed solvent and dichloromethane-methanol mixed solvent to obtain six eluent fractions, named A-F. Compound D was separated by silica gel column chromatography, Sephadex LH-20 column chromatography, and semi-preparative HPLC to obtain compound I-2. Compound F was separated by Sephadex LH-20 column chromatography and semi-preparative HPLC to obtain compounds I-1 and I-3. Compound I-1 was separated by a chiral HPLC column to obtain enantiomers I-(+)-1 and I-(–)-1. The four alkaloids of this invention have a pH range of 13.65–14.16. m At concentrations of M, it can significantly inhibit the activity of human carboxylesterase 2. Therefore, it can be applied to the preparation of attenuated and protective agents for anticancer drugs such as irinotecan.

The present invention belongs to the field of medicine and relates to use of an iron-loaded carbon nanoparticle suspension injection for combined administration. The iron-loaded carbon nanoparticle suspension injection is administered in combination with an anticancer drug to inhibit tumor growth. In the combined administration, the anticancer drug is administered orally or intravenously, and the iron-loaded carbon nanoparticle suspension injection is administered via intratumoral injection. After the iron-loaded carbon nanoparticle suspension injection is injected into a tumor, it is found that the anticancer drug administered orally or intravenously is enriched in the tumor, thereby increasing the concentration of the anticancer drug in the tumor, enabling the anticancer drug to more accurately act on the tumor site, and reducing the dose of the anticancer drug and its toxic side effects on normal cells and tissues. The combined administration of the iron-loaded carbon nanoparticle suspension injection and the anticancer drug has a synergistic effect.

The application relates to the technical field of biological medicine, in particular to a medicine for combined treatment of tumors by using a recombinant oncolytic virus and a small-molecule anticancer drug. The method comprises the following steps: combined treatment of tumors by using a recombinant oncolytic virus and a small-molecule anticancer drug; the small-molecule anticancer drug is a small-molecule anticancer drug targeting EGFR; the recombinant oncolytic virus comprises M protein, G protein, N protein, P protein and L protein after site-directed mutagenesis. The application can kill tumor cells by using a recombinant oncolytic virus and a small-molecule anticancer drug, and the curative effect is 1+1>2.

The present invention relates to a compound capable of preventing or treating lung cancer by inhibiting the expression or activity of Anoctamin 1 (ANO1), which is a calcium-activated chloride channel, and epidermal growth factor receptor (EGFR), which is an epithelial growth factor receptor. The compound of the present invention can be advantageously used alone as a composition for preventing or treating lung cancer, can be used per se as a dual-target anticancer drug for ANO1 and EGFR, and can also be used as an adjuvant or a combination preparation in combination with an EGFR-targeted therapeutic agent.

The present invention relates to a biomarker for measuring anticancer drug resistance comprising a gene expressed in a group of cancer cells, wherein the gene releases an anticancer drug that has penetrated into the group of cancer cells to the outside of the group of cancer cells, wherein the gene comprises a gene selected from the group consisting of ABCG1, p-STAT3, STAT3, p-AKT, AKT, p-ERK, ERK, β-actin, ACTA2, GAS6, FAP, PDPN, COL1A1, AXL, and combinations thereof.

The present invention relates to anticancer drug-resistant and sensitive liver cancer cell lines, and a method for screening liver cancer therapeutic agents by using same. Specifically, provided are a liver cancer cell line PLLC15 (Accession No. 00000) that does not have sorafenib resistance and / or a liver cancer cell line PLLC15_Sora (Accession No. 00000) that has sorafenib resistance, or a composition for screening anticancer agents including one or more thereof, and a method for screening anticancer agents, and thus an anticancer immunotherapeutic agent or method using immune function of an experimental animal can be screened and time and cost can be reduced by reviewing in advance a sorafenib resistance problem in the development stage of liver cancer therapeutic agents.

This invention relates to the field of oncology technology, specifically to the application of a polypeptide encoded by the circular RNA circHDAC5 in the preparation of anticancer drugs. The amino acid sequence is shown in SEQ ID NO.1. The anticancer drug is used to inhibit colorectal cancer, specifically to inhibit the proliferation and / or metastasis of colorectal cancer cells. This polypeptide is formed by backsplicing exons 13-16 of the HDAC5 gene and can inhibit the proliferation and metastasis of colorectal cancer in both in vivo and in vitro environments. It can effectively inhibit the malignant biological behavior of colorectal cancer cells and can be used to prepare targeted therapeutic drugs for colorectal cancer.

This disclosure relates to the field of anticancer drug technology, and discloses a 7-azaindole compound, its synthesis method, and its uses. The structure of the 7-azaindole compound is as follows: This 7-azaindole compound can be used as a fluorescent polarization probe or a degradation chemical probe targeting CSN5; wherein, the fluorescent polarization chemical probe has a good binding affinity to the metalloproteinase CSN5, laying an important foundation for the discovery of novel CSN5 inhibitors; at the same time, the degradation chemical probe exhibits good enzyme-level activity and cell-inhibitory activity, and has the potential to degrade CSN5 protein and its variants, providing a material basis for the development of related drugs targeting CSN5 and the study of its biological functions, and also has great potential in the discovery of cancer immunotherapy drugs and the treatment of other related diseases.

The present invention relates to a dual-targeted anticancer agent that targets both a cancer cell-specific receptor and CP2c, and a production method therefor. The dual-targeted anticancer agent exhibits excellent target specificity by binding to a cancer cell-specific target and exhibits excellent anticancer efficacy by targeting CP2c, which is an intracellular protein, and thus can be effectively used for the treatment of cancer.

This invention provides a method and application for evaluating tumor drugs based on PBMCs and prostate organoids, belonging to the field of biotechnology. The method includes the following steps: (1) Construction of tumor organoids: pre-treating excised tissue to obtain cell clusters, encapsulating the cell clusters with Matrigel, plate-coating, and adding tumor organoid culture medium for culture; (2) Isolating peripheral blood mononuclear cells; (3) Co-culturing peripheral blood mononuclear cells with tumor organoids to obtain CTL cells; (4) Co-culturing CTL cells with tumor organoids, treating the co-culture mixture with tumor drugs, and judging the efficacy of tumor drugs. The tumor drug evaluation method based on PBMCs and prostate organoids provided by this invention utilizes the fact that tumor organoids can more closely reproduce the tumor microenvironment, and more accurately evaluate the efficacy of anticancer drugs.

The application belongs to the field of medicine, and particularly relates to application of a benzothiazepine compound in preparation of a cancer treatment drug, wherein the benzothiazepine compound has a structural formula as shown in formula I, and the cancer is at least one selected from liver cancer, intestinal cancer, bone cancer and lung cancer. According to a cell activity experiment of the application, it is found that the compound shown in formula I shows clear and different activities on human liver cancer cells, human lung cancer cells, human osteosarcoma cells and human colorectal cancer cells in vitro. The inventors of the application find, for the first time, through activity screening on a small molecule skeleton, that the benzothiazepine compound shown in formula I has excellent activity on various different types of human tumors, and the benzothiazepine compound provides an optional scheme for a broad-spectrum anticancer drug.